Remedor Biomed is a pioneering biotechnology company that is poised to become a leader in the wound care and regenerative medicine markets. Focused on developing innovative solutions for the wound care market, with a particular emphasis on diabetic foot ulcers (DFUs) and severe burns, the company's flagship product, WoundaGel, has the potential to revolutionize the treatment of chronic skin wounds, offering hope to millions of patients globally. With a strong intellectual property portfolio, Remedor Biomed combines cutting-edge research and development with a commitment to delivering effective solutions for patients.